596 PATENT ABSTRACTS

The present invention relates to a method for protecting hernatopoietic stem cells from the myelotoxicity of chemotherapeutic drugs or radiation therapy, which comprises, ad- ministering to a subject a therapeutically effec- tive amount of transforming growth factor beta 1 for protecting bone marrow from the myelotoxicity of chemotherapeutic drugs or radiation therapy. The TGF betal may be ad- ministered prior (e.g. 24 hours) to the ad- ministration of the chemotherapeutic drugs or radiation therapy~ Preferably, the TGF betal is administered to the subject in an amount of ab- out 5 mug to 25 mug per kg body weight. The patient or subject of the present invention may be a mammal (e.g. human, domestic animal such as horse, cow, dog, cat or pig) and is preferably a human being. The mode of administration is either by interfemoral arterial, interperitoneally or subcutaneously, and preferably is by injec- tion.

5278285

V A R I A N T O F K U N I T Z - T Y P E I N H I B I T O R D E R I V E D F R O M T H E

A L P H A 3 - C H A I N O F H U M A N T Y P E VI C O L L A G E N P R O D U C E D

B Y R E C O M B I N A N T D N A T E C H N O L O G Y

Juergen Ebbers, Dietrich Hoerlein, Ruppert Timpl, Mon-Li Chu, Wuppertal, Federal Republic Of Germany assigned to Bayer Ak- tiengesellschaft

Kunitz-type inhibitor derived from the alpha3- chain of human type VI collagen produced by recombinant DNA technology, variants thereof, process, expression vector and recombinant host therefore and pharmaceutical use thereof are dis- closed.

to homogenity of intact recombinant human im- mune interferon.

5278290

B I N D I N G P R O T E I N F O R C E A A N D U S E S T H E R E O F

Pete Thomas, Carol A Toth, Sibusisiwe M Maswoswe, Joseph Briggman assigned to Applied Biotechnology Inc; New England Deaconess Hospital Corp

Disclosed is a protein that specifically binds car- cinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 21 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO: 2. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a pat- ient for carcinoma.

5279822

M O N O C L O N A L A N T I B O D I E S A G A I N S T T H E 2 8 K D P R O T E I N O F

S. M A N S O N I

Jean-Marc Balloul, Raymond Pierce, Jean- Marie Grzych, Andre Capron, Lille, France as- signed to lnstitut Pasteur; Institut Pasteur de Lillelnstitut National de la Sante et de la Recher- che Medica

A hybridoma is provided which provides a monoclonal antibody of isotope IgG2a, which recognizes a strip corresponding to a peptidic fragment of 8kD, isolated by controlled pro- teolysis of the 28kD polypeptide of S. mansoni.

5278286

I M M U N E I N T E R F E R O N 5279823

Hsiang-Fu Kung, Hiromu Sugino, Susumu Honda assigned to Hoffmann-La Roche Inc

An intact human immune interferon protein and a method for the extraction and purification of intact recombinant human immune interferon is disclosed. This method permits the purification

PURIFIED FORMS OF DNASE

John Frenz, Steven J Shire, Mary B Sliwkowski assigned to Genentech Inc

The present invention provides the identifica- tion and characterization of two components of